Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Buy
57
IVBIY Quote, Financials, Valuation and Earnings
Last price:
$44.50
Seasonality move
:
6.47%
Day range:
$44.50 - $44.50
52-week range:
$22.29 - $52.00
Dividend yield:
0%
P/E ratio:
172.95x
P/S ratio:
10.21x
P/B ratio:
10.94x
Volume:
--
Avg. volume:
90
1-year change:
99.61%
Market cap:
$19B
Revenue:
$1.8B
EPS (TTM):
$0.26
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
IVBIY
Innovent Biologics, Inc.
|
-- | -- | -- | -- | -- |
|
CSPCY
CSPC Pharmaceutical Group Ltd.
|
-- | -- | -- | -- | -- |
|
SVA
Sinovac Biotech Ltd.
|
-- | -- | -- | -- | -- |
|
ZLAB
Zai Lab Ltd.
|
$120.8M | -$0.49 | 10.78% | -4.05% | $38.47 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
IVBIY
Innovent Biologics, Inc.
|
$44.50 | -- | $19B | 172.95x | $0.00 | 0% | 10.21x |
|
CSPCY
CSPC Pharmaceutical Group Ltd.
|
$5.10 | -- | $14.6B | 27.14x | $0.07 | 2.41% | 4.07x |
|
SVA
Sinovac Biotech Ltd.
|
$6.47 | -- | $464.9M | -- | $55.00 | 0% | 1.50x |
|
ZLAB
Zai Lab Ltd.
|
$20.41 | $38.47 | $2.3B | -- | $0.00 | 0% | 4.87x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
IVBIY
Innovent Biologics, Inc.
|
17.68% | 0.382 | -- | 2.16x |
|
CSPCY
CSPC Pharmaceutical Group Ltd.
|
1.2% | 1.347 | -- | 1.93x |
|
SVA
Sinovac Biotech Ltd.
|
3.46% | 7.237 | 12.91% | 11.22x |
|
ZLAB
Zai Lab Ltd.
|
23.86% | 0.688 | 11.48% | 2.18x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
IVBIY
Innovent Biologics, Inc.
|
-- | -- | -0.6% | -0.75% | -- | -- |
|
CSPCY
CSPC Pharmaceutical Group Ltd.
|
$646.8M | $205.9M | 12.94% | 12.37% | 25.7% | -- |
|
SVA
Sinovac Biotech Ltd.
|
-- | -- | -1.02% | -1.05% | -- | -- |
|
ZLAB
Zai Lab Ltd.
|
$65.6M | -$69.7M | -17.96% | -22.45% | -54.4% | -$19.1M |
Innovent Biologics, Inc. vs. Competitors
-
Which has Higher Returns IVBIY or CSPCY?
CSPC Pharmaceutical Group Ltd. has a net margin of -- compared to Innovent Biologics, Inc.'s net margin of 21.07%. Innovent Biologics, Inc.'s return on equity of -0.75% beat CSPC Pharmaceutical Group Ltd.'s return on equity of 12.37%.
Company Gross Margin Earnings Per Share Invested Capital IVBIYInnovent Biologics, Inc.-- -- $2.2B CSPCYCSPC Pharmaceutical Group Ltd.67.08% $0.07 $4.7B -
What do Analysts Say About IVBIY or CSPCY?
Innovent Biologics, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand CSPC Pharmaceutical Group Ltd. has an analysts' consensus of -- which suggests that it could fall by --. Given that Innovent Biologics, Inc. has higher upside potential than CSPC Pharmaceutical Group Ltd., analysts believe Innovent Biologics, Inc. is more attractive than CSPC Pharmaceutical Group Ltd..
Company Buy Ratings Hold Ratings Sell Ratings IVBIYInnovent Biologics, Inc.0 0 0 CSPCYCSPC Pharmaceutical Group Ltd.0 0 0 -
Is IVBIY or CSPCY More Risky?
Innovent Biologics, Inc. has a beta of 0.344, which suggesting that the stock is 65.568% less volatile than S&P 500. In comparison CSPC Pharmaceutical Group Ltd. has a beta of 0.555, suggesting its less volatile than the S&P 500 by 44.517%.
-
Which is a Better Dividend Stock IVBIY or CSPCY?
Innovent Biologics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CSPC Pharmaceutical Group Ltd. offers a yield of 2.41% to investors and pays a quarterly dividend of $0.07 per share. Innovent Biologics, Inc. pays -- of its earnings as a dividend. CSPC Pharmaceutical Group Ltd. pays out 52% of its earnings as a dividend. CSPC Pharmaceutical Group Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios IVBIY or CSPCY?
Innovent Biologics, Inc. quarterly revenues are --, which are smaller than CSPC Pharmaceutical Group Ltd. quarterly revenues of $964.2M. Innovent Biologics, Inc.'s net income of -- is lower than CSPC Pharmaceutical Group Ltd.'s net income of $203.2M. Notably, Innovent Biologics, Inc.'s price-to-earnings ratio is 172.95x while CSPC Pharmaceutical Group Ltd.'s PE ratio is 27.14x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Innovent Biologics, Inc. is 10.21x versus 4.07x for CSPC Pharmaceutical Group Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IVBIYInnovent Biologics, Inc.10.21x 172.95x -- -- CSPCYCSPC Pharmaceutical Group Ltd.4.07x 27.14x $964.2M $203.2M
-
Which has Higher Returns IVBIY or SVA?
Sinovac Biotech Ltd. has a net margin of -- compared to Innovent Biologics, Inc.'s net margin of --. Innovent Biologics, Inc.'s return on equity of -0.75% beat Sinovac Biotech Ltd.'s return on equity of -1.05%.
Company Gross Margin Earnings Per Share Invested Capital IVBIYInnovent Biologics, Inc.-- -- $2.2B SVASinovac Biotech Ltd.-- -- $11.8B -
What do Analysts Say About IVBIY or SVA?
Innovent Biologics, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Sinovac Biotech Ltd. has an analysts' consensus of -- which suggests that it could fall by --. Given that Innovent Biologics, Inc. has higher upside potential than Sinovac Biotech Ltd., analysts believe Innovent Biologics, Inc. is more attractive than Sinovac Biotech Ltd..
Company Buy Ratings Hold Ratings Sell Ratings IVBIYInnovent Biologics, Inc.0 0 0 SVASinovac Biotech Ltd.0 0 0 -
Is IVBIY or SVA More Risky?
Innovent Biologics, Inc. has a beta of 0.344, which suggesting that the stock is 65.568% less volatile than S&P 500. In comparison Sinovac Biotech Ltd. has a beta of 0.887, suggesting its less volatile than the S&P 500 by 11.313%.
-
Which is a Better Dividend Stock IVBIY or SVA?
Innovent Biologics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sinovac Biotech Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $55.00 per share. Innovent Biologics, Inc. pays -- of its earnings as a dividend. Sinovac Biotech Ltd. pays out -328.35% of its earnings as a dividend.
-
Which has Better Financial Ratios IVBIY or SVA?
Innovent Biologics, Inc. quarterly revenues are --, which are smaller than Sinovac Biotech Ltd. quarterly revenues of --. Innovent Biologics, Inc.'s net income of -- is lower than Sinovac Biotech Ltd.'s net income of --. Notably, Innovent Biologics, Inc.'s price-to-earnings ratio is 172.95x while Sinovac Biotech Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Innovent Biologics, Inc. is 10.21x versus 1.50x for Sinovac Biotech Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IVBIYInnovent Biologics, Inc.10.21x 172.95x -- -- SVASinovac Biotech Ltd.1.50x -- -- --
-
Which has Higher Returns IVBIY or ZLAB?
Zai Lab Ltd. has a net margin of -- compared to Innovent Biologics, Inc.'s net margin of -39.51%. Innovent Biologics, Inc.'s return on equity of -0.75% beat Zai Lab Ltd.'s return on equity of -22.45%.
Company Gross Margin Earnings Per Share Invested Capital IVBIYInnovent Biologics, Inc.-- -- $2.2B ZLABZai Lab Ltd.51.15% -$0.46 $939.8M -
What do Analysts Say About IVBIY or ZLAB?
Innovent Biologics, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Zai Lab Ltd. has an analysts' consensus of $38.47 which suggests that it could grow by 88.47%. Given that Zai Lab Ltd. has higher upside potential than Innovent Biologics, Inc., analysts believe Zai Lab Ltd. is more attractive than Innovent Biologics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings IVBIYInnovent Biologics, Inc.0 0 0 ZLABZai Lab Ltd.8 1 0 -
Is IVBIY or ZLAB More Risky?
Innovent Biologics, Inc. has a beta of 0.344, which suggesting that the stock is 65.568% less volatile than S&P 500. In comparison Zai Lab Ltd. has a beta of 0.859, suggesting its less volatile than the S&P 500 by 14.084%.
-
Which is a Better Dividend Stock IVBIY or ZLAB?
Innovent Biologics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Zai Lab Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Innovent Biologics, Inc. pays -- of its earnings as a dividend. Zai Lab Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IVBIY or ZLAB?
Innovent Biologics, Inc. quarterly revenues are --, which are smaller than Zai Lab Ltd. quarterly revenues of $128.2M. Innovent Biologics, Inc.'s net income of -- is lower than Zai Lab Ltd.'s net income of -$50.6M. Notably, Innovent Biologics, Inc.'s price-to-earnings ratio is 172.95x while Zai Lab Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Innovent Biologics, Inc. is 10.21x versus 4.87x for Zai Lab Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IVBIYInnovent Biologics, Inc.10.21x 172.95x -- -- ZLABZai Lab Ltd.4.87x -- $128.2M -$50.6M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
46
Is NVDA Stock a Buy?
Market Cap: $4.3T
P/E Ratio: 36x
Sell
49
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 34x
Sell
40
Is GOOGL Stock a Buy?
Market Cap: $3.6T
P/E Ratio: 27x
Alerts
Buy
51
AAOI alert for Apr 5
Applied Optoelectronics, Inc. [AAOI] is up 20.3% over the past day.
Buy
59
SBAC alert for Apr 4
SBA Communications Corp. [SBAC] is up 18.96% over the past day.
Buy
55
VSAT alert for Apr 4
ViaSat, Inc. [VSAT] is up 18.73% over the past day.
